Product
Citarinostat
1 clinical trial
1 indication
Indication
Smoldering Plasma Cell MyelomaClinical trial
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-09-15